Unveiling CN Bio's PhysioMimix DILI Assay Kit
CN Bio, a pioneering name in Organ-on-a-chip (OOC) technology for drug discovery, has recently launched its advanced PhysioMimix DILI Assay Kit: Human 24. This innovative kit is poised to revolutionize preclinical toxicology testing, providing critical insights into drug safety that could transform how therapeutic candidates are evaluated.
Advancing Drug Safety with the DILI Assay Kit
In today's complex landscape of drug development, a significant percentage of drug candidates—approximately 30%—fail during clinical trials. Alarmingly, hepatotoxicity is responsible for 18% of these failures. Existing methodologies primarily rely on a mix of in vitro tests, in vivo animal models, and in silico simulations. These traditional approaches often fall short due to their limited sensitivity and relevance to human physiology.
Overcoming Limitations in Preclinical Testing
CN Bio's liver microphysiological system (MPS) has been FDA-recognized and is designed explicitly to address the shortcomings of current methods. The DILI assay kit builds upon this foundation, offering a streamlined solution to yield comprehensive, human-specific insights that accurately inform drug-induced liver injury (DILI).
Simplifying Preclinical Drug Development
The DILI assay launched by CN Bio evolved from their contract research services (CRS) into an easy-to-use, all-in-one kit. This transition reflects the increasing demand for faster, more reliable results in toxicology testing. The kit aims to facilitate deeper understandings of mechanistic hepatotoxicity while simplifying the adoption process for users new to MPS technologies.
Features of the PhysioMimix DILI Assay Kit
One of the standout features of the DILI assay kit is its capacity to maintain functional and metabolically active hepatic cultures under perfusion for up to two weeks. It incorporates Kupffer cells, providing significant insights into the human immune system while allowing researchers to study complex toxicology events over extended periods.
Efficient Screening for Drug Candidates
The DILI assay kit provides 24 wells that enable simultaneous assessment of up to eight different conditions in triplicate. This substantial data output allows researchers to efficiently screen drug candidates, facilitating early detection of issues related to drug safety and ultimately reducing both time and costs associated with drug development.
Expert Insights on the DILI Assay Kit
Dr. Ovidiu Novac, Senior Scientist and Project Manager for the DILI assay kit, expressed insights into the importance of this development. He stated, "Toxicology testing is a cornerstone in drug development, yet current methods often cannot meet the requirements, leading to expensive failures later in the process. Our new DILI assay kit can easily replicate our established assays in laboratories, offering valuable mechanistic insights into hepatotoxicity and supporting more confident transitions to clinical trials."
Frequently Asked Questions
What is the PhysioMimix DILI Assay Kit?
The PhysioMimix DILI Assay Kit is an advanced solution for preclinical toxicology testing, designed by CN Bio to provide insights into drug-induced liver injury.
Why was the DILI assay kit developed?
It was developed to address the growing need for effective, human-relevant toxicology testing methods that can streamline drug development workflows.
How does the kit enhance drug safety evaluations?
The kit allows researchers to generate robust human-specific data, significantly improving the understanding of potential hepatotoxicity in drug candidates.
What unique features does the DILI Assay Kit offer?
It includes 24 wells for testing multiple conditions and utilizes liver microphysiological systems to mimic human responses more accurately.
Who can benefit from using the DILI Assay Kit?
Pharmaceutical companies, contract research organizations, and academic researchers engaged in drug discovery and development stand to benefit from this innovative kit.
